Lantheus (NASDAQ:LNTH) Shares Break Below Fifty Day Moving Average – Here’s Why

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $100.48 and traded as low as $100.08. Lantheus shares last traded at $100.12, with a volume of 520,129 shares.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LNTH. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Finally, TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Lantheus has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Price Performance

The stock has a 50 day moving average of $100.49 and a two-hundred day moving average of $96.87. The stock has a market cap of $6.54 billion, a PE ratio of 24.19 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.57 earnings per share. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.

Hedge Funds Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ABS Investment Management LLC acquired a new position in Lantheus during the second quarter worth $232,974,000. Western Wealth Management LLC acquired a new stake in shares of Lantheus in the first quarter worth about $25,000. Allworth Financial LP acquired a new stake in shares of Lantheus in the second quarter worth about $49,000. Bessemer Group Inc. boosted its stake in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Lantheus by 122.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider’s stock worth $55,000 after acquiring an additional 306 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.